Top-line data for its phase 2b trial studying GH001 is expected either in the fourth quarter of 2024 or the first quarter of ...

Net Loss: Net loss attributable to common stockholders for the third quarter of 2024 was $ (3.1) million, or $ (1.92) per ...

SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today reported financial results for the quarter ended ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...

Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the ...

For the third quarter of 2024, Ascendis Pharma reported a net loss of €99.2 million, or €1.72 per share (basic and diluted) ...

Ami Bhatt asks Kate Dalton to share details on the challenges of early feasibility studies from her perspective as a clinical site coordinator.